Darzalex SC (daratumumab)

pCPA File Number: 21759

Negotiation Status:

Concluded with an LOI

Indication(s):

Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.

Sponsor/Manufacturer:

Janssen Inc.

CADTH Project Number:

PC0257

pCPA Engagement Letter Issued:

2022-03-04

Negotiation Process Concluded:

2022-03-11